PRGO
NYSE · Pharmaceuticals
Perrigo Co Plc
$14.71
-0.18 (-1.21%)
Financial Highlights (FY 2026)
Revenue
4.38B
Net Income
-171,909,582
Gross Margin
35.3%
Profit Margin
-3.9%
Rev Growth
+1.9%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.3% | 35.3% | 30.7% | 30.7% |
| Operating Margin | 2.4% | 2.2% | 18.2% | 20.0% |
| Profit Margin | -3.9% | -3.7% | 17.4% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.38B | 4.30B | 733.03M | 632.45M |
| Gross Profit | 1.54B | 1.52B | 225.36M | 194.44M |
| Operating Income | 106.34M | 93.96M | 133.71M | 126.60M |
| Net Income | -171,909,582 | -151,893,406 | 127.46M | 109.75M |
| Gross Margin | 35.3% | 35.3% | 30.7% | 30.7% |
| Operating Margin | 2.4% | 2.2% | 18.2% | 20.0% |
| Profit Margin | -3.9% | -3.7% | 17.4% | 17.4% |
| Rev Growth | +1.9% | +1.9% | +2.0% | -3.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 460.91M | 460.91M | 149.00M | 136.39M |
| Total Equity | 550.28M | 550.28M | 768.79M | 740.72M |
| D/E Ratio | 0.84 | 0.84 | 0.19 | 0.18 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 434.97M | 405.68M | 189.96M | 150.29M |
| Free Cash Flow | — | — | 136.11M | 128.72M |